NCT06950645 - Clinical Trial on the Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells) | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

March 27, 2024

Primary Completion Date

December 19, 2025

Study Completion Date

March 14, 2026

Conditions

Rotavirus Gastroenteritis

Interventions

BIOLOGICAL

Oral hexavalent reassortant rotavirus attenuated live vaccine

Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally

BIOLOGICAL

Oral hexavalent reassortant rotavirus attenuated live vaccine

Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally

BIOLOGICAL

Oral hexavalent reassortant rotavirus attenuated live vaccine

Oral hexavalent reassortant rotavirus attenuated live vaccine (low-dose) three doses administered orally

BIOLOGICAL

Placebo

Placebo of experimental vaccine for infants three doses administered orally

BIOLOGICAL

Oral hexavalent reassortant rotavirus attenuated live vaccine

Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally

BIOLOGICAL

Placebo

Placebo of experimental vaccine for infants three doses administered orally

Trial Locations (1)

Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang

All Listed Sponsors

lead

Sinovac Life Sciences Co., Ltd.

INDUSTRY